Physician profile
Leslie Klein
NPI 1215151006
$6,197.10
in general payments reported to CMS, 2019-2025
41 companies · $885 in 2025
The $885 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $534 · 2021: $866 · 2022: $651 · 2023: $1,394 · 2024: $1,180 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,284.28 | 2019-2025 | |
| Novo Nordisk INC | $862.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.17 | 2019-2025 | Jardiance |
| Abbott Laboratories | $378.92 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $354.07 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $336.72 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Corcept Therapeutics | $278.34 | 2019-2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.06 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $202.30 | 2020-2024 | Farxiga |
| Sumitomo Pharma America, INC. | $201.50 | 2024-2025 | Orgovyx |
| Janssen Pharmaceuticals, INC | $165.02 | 2019-2021 | |
| Eisai INC. | $124.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.16 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.65 | 2024-2025 | Caplyta |
| Pfizer INC. | $101.58 | 2021-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.25 | 2019-2023 | |
| Glaxosmithkline, LLC. | $76.79 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $55.90 | 2020-2021 | |
| Radius Health, INC. | $53.62 | 2020-2021 | |
| Astellas Pharma US INC | $48.25 | 2025 | Xtandi |
| Sanofi Pasteur INC. | $47.64 | 2023-2024 | |
| Phadia US INC. | $46.70 | 2021 | |
| Medtronic, INC. | $42.98 | 2021 | |
| Amgen INC. | $40.72 | 2025 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $40.21 | 2023-2025 | Gvoke Hypopen |
| Cardiovascular Systems INC. | $32.76 | 2019 | |
| Zealand Pharma US, INC. | $31.22 | 2021-2022 | |
| Exact Sciences Corporation | $27.12 | 2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $26.92 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $26.55 | 2025 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $22.35 | 2021 | |
| Lundbeck LLC | $21.74 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $21.18 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.15 | 2023 | Quviviq |
| Alk-Abello, INC | $19.60 | 2025 | Grastek, Odactra, Ragwitek |
| Valeritas, INC. | $18.91 | 2019 | |
| Celgene Corporation | $15.46 | 2023 | |
| Hikma Pharmaceuticals USA | $13.96 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.67 | 2025 | Rexulti |
| Cequr Corporation | $12.99 | 2025 | Cequr Simplicity |
| Arbor Pharmaceuticals, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.